Vaxxinity Inc


Prices are adjusted according to historical splits.

Vaxxinity Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$264.90 million
Book Value:
Revenue TTM:
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Vaxxinity Inc had its IPO on 2021-11-11 under the ticker symbol VAXX.

The company operates in the Healthcare sector and Biotechnology industry. Vaxxinity Inc has a staff strength of 87 employees.

Stock update

Shares of Vaxxinity Inc opened at $1.77 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.59 - $1.86, and closed at $1.6.

This is a -9.6% slip from the previous day's closing price.

A total volume of 298,315 shares were traded at the close of the day’s session.

In the last one week, shares of Vaxxinity Inc have slipped by -23.45%.

Vaxxinity Inc's Key Ratios

Vaxxinity Inc has a market cap of $264.90 million, indicating a price to book ratio of 2.9213 and a price to sales ratio of 4604.903.

In the last 12-months Vaxxinity Inc’s revenue was $-1000 with a gross profit of $-1871000 and an EBITDA of $-71711000. The EBITDA ratio measures Vaxxinity Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Vaxxinity Inc’s operating margin was 0% while its return on assets stood at -41.1% with a return of equity of -94.94%.

In Q2, Vaxxinity Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 57.3%.

Vaxxinity Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-0.53 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Vaxxinity Inc’s profitability.

Vaxxinity Inc stock is trading at a EV to sales ratio of 1898.0251 and a EV to EBITDA ratio of -1.4443. Its price to sales ratio in the trailing 12-months stood at 4604.903.

Vaxxinity Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$71.37 million
Total Liabilities
$23.78 million
Operating Cash Flow
$26.61 million
Capital Expenditure
Dividend Payout Ratio

Vaxxinity Inc ended 2023 with $71.37 million in total assets and $0 in total liabilities. Its intangible assets were valued at $71.37 million while shareholder equity stood at $35.01 million.

Vaxxinity Inc ended 2023 with $0 in deferred long-term liabilities, $23.78 million in other current liabilities, 279000.00 in common stock, $-337101000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $37.06 million and cash and short-term investments were $55.85 million. The company’s total short-term debt was $1,392,000 while long-term debt stood at $12.34 million.

Vaxxinity Inc’s total current assets stands at $59.71 million while long-term investments were $0 and short-term investments were $18.79 million. Its net receivables were $407000.00 compared to accounts payable of $1.89 million and inventory worth $2.75 million.

In 2023, Vaxxinity Inc's operating cash flow was $26.61 million while its capital expenditure stood at $90000.

Comparatively, Vaxxinity Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Vaxxinity Inc stock is currently trading at $1.6 per share. It touched a 52-week high of $4.47 and a 52-week low of $4.47. Analysts tracking the stock have a 12-month average target price of $12.5.

Its 50-day moving average was $2.36 and 200-day moving average was $2.26 The short ratio stood at 35.86 indicating a short percent outstanding of 0%.

Around 5104.8% of the company’s stock are held by insiders while 2271.9% are held by institutions.

Frequently Asked Questions About Vaxxinity Inc

The stock symbol (also called stock or share ticker) of Vaxxinity Inc is VAXX

The IPO of Vaxxinity Inc took place on 2021-11-11

Similar Industry Stocks (Biotechnology)

Last Price
Mitesco Inc (MITID)

Most Active

Last Price
Amyris Inc (AMRS)
Humbl Inc (HMBL)

Top Gainers

Last Price
Latch Inc (LTCHW)

Top Losers

Last Price


Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer’s disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson’s disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and VXX-301, an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; VXX-401 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Merritt Island, Florida.


1717 Main Street, Dallas, TX, United States, 75201